191 related articles for article (PubMed ID: 18754028)
1. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Klapper W; Stoecklein H; Zeynalova S; Ott G; Kosari F; Rosenwald A; Loeffler M; Trümper L; Pfreundschuh M; Siebert R;
Leukemia; 2008 Dec; 22(12):2226-9. PubMed ID: 18754028
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.
Zhang HW; Chen ZW; Li SH; Bai W; Cheng NL; Wang JF
Hematol Oncol; 2011 Dec; 29(4):185-9. PubMed ID: 21692100
[TBL] [Abstract][Full Text] [Related]
3. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
4. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
5. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
[TBL] [Abstract][Full Text] [Related]
8. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Aug; 62(8):754-6. PubMed ID: 19638549
[TBL] [Abstract][Full Text] [Related]
9. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
[TBL] [Abstract][Full Text] [Related]
10. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
11. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
12. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement.
Barth TF; Müller S; Pawlita M; Siebert R; Rother JU; Mechtersheimer G; Kitinya J; Bentz M; Möller P
J Pathol; 2004 Aug; 203(4):940-5. PubMed ID: 15258997
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
15. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
16. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
17. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
[TBL] [Abstract][Full Text] [Related]
18. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
19. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
